Search results
Showing 101 to 150 of 1595 results for nice quality standards or clinical guidelines
Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.
Stroke and ischaemic attack: early supported discharge (IND32)
This indicator covers the proportion of people who had a stroke that are supported by a skilled stroke early supported discharge team. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG49
Training resources for those working in social care
This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.
Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.
This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.
Show all sections
Sections for NG12
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
This guideline covers the care of women and their babies during labour and immediately after birth. It focuses on women who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)
The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.
Show all sections
Early value assessment (EVA) guidance on artificial intelligence technologies to aid contouring for radiotherapy treatment planning in people having external be...
View recommendations for HTE11Show all sections
KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication (HTE10)
Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication....
This quality standard covers assessing, diagnosing and managing chronic obstructive pulmonary disease (COPD). It describes high-quality care in priority areas for improvement.
View quality statements for QS10Show all sections
Sections for QS10
- Quality statements
- Quality statement 1: Diagnosis with spirometry
- Quality statement 2: Inhaler technique
- Quality statement 3: Assessment for long-term oxygen therapy
- Quality statement 4: Pulmonary rehabilitation for stable COPD and exercise limitation
- Quality statement 5: Pulmonary rehabilitation after an acute exacerbation
- Quality statement 6: Emergency oxygen during an exacerbation
- Quality statement 7: Non-invasive ventilation
patients, and that they can manufacture the medicine to the required quality. At NICE we do not license medicines - you can...
Evidence-based recommendations on transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves injecting a high-speed jet of water into the prostate to destroy some of the prostate tissue and widen the urethra.
View recommendations for IPG770Show all sections
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Spinal metastases and metastatic spinal cord compression (NG234)
This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)
Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.
Spinal metastases and metastatic spinal cord compression (QS56)
This quality standard covers diagnosis and management of spinal metastases and metastatic spinal cord compression. It describes high-quality care in priority areas for improvement.
View quality statements for QS56Show all sections
Sections for QS56
- Quality statements
- Quality statement 1: Information about recognising the symptoms of metastatic spinal cord compression
- Quality statement 2: Imaging and treatment plans for adults with suspected spinal metastases
- Quality statement 3: Imaging for adults with suspected metastatic spinal cord compression
- Quality statement 4: Coordinating investigations for adults with suspected metastatic spinal cord compression
- Quality statement 5: Coordinating care for adults with metastatic spinal cord compression
- Quality statement 6: Radiotherapy for metastatic spinal cord compression
- Quality statement 7: Supportive care and rehabilitation
Find out more about quality standards advisory committee 2 members at NICE
An advisory service from the UK’s National Institute for Health and Care Excellence to help other countries improve their nation’s health and wellbeing
Get expert advice and support from NICE International, part of the UK’s National Institute for Health and Care Excellence, for a project in your country
This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.
Resources to help with planning ahead for NICE guidance, understanding where you are now, and conducting improvement initiatives.
Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care
Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)
This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.
Information and benefits about shared decision making. Includes links to patient decision aids.
Our experts can offer advice and support in contextualising our guidelines, or helping you adapt our content to your country or local context.
Kidney conditions: CKD and blood pressure when ACR 70 or more (IND264)
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 125/75 mmHg if using ambulatory or home monitoring, or less than 130/80 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM248.
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without diabetes, who are currently treated with an ARB or an ACE inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM247
This indicator covers the percentage of patients on the CKD register and currently treated with an ARB or an ACE inhibitor who are also currently treated with an SGLT2 inhibitor if they have either: no type 2 diabetes and a urine ACR of 22.6 mg/mmol or more, or type 2 diabetes and a urine ACR 3 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM246
Lipid disorders: FH assessment and diagnosis (new readings) (IND261)
This indicator covers the percentage of patients with a total cholesterol reading in the preceding 12 months greater than 7.5 mmol/litre who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM245
Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)
This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244
This indicator covers the contractor establishing and maintaining a register of patients with stroke or transient ischaemic attack (TIA). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM243
This indicator covers the contractor establishing and maintaining a register of patients in need of palliative care or support. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM242
Bipolar, schizophrenia and other psychoses: register (IND257)
This indicator covers the contractor establishing and maintaining a register of patients with schizophrenia, bipolar affective disorder and other psychoses. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM241
Bipolar, schizophrenia and other psychoses: register (lithium therapy) (IND256)
This indicator covers the contractor establishing and maintaining a register of patients with schizophrenia, bipolar affective disorder and other psychoses, and other patients on lithium therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM240
This indicator covers the contractor establishing and maintaining a register of patients with established hypertension. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM239
This indicator covers the contractor establishing and maintaining a register of patients aged 18 or over with heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM238
This indicator covers the contractor establishing and maintaining a register of patients aged 18 or over receiving drug treatment for epilepsy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM237
This indicator covers the contractor establishing and maintaining a register of patients diagnosed with dementia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM236
This indicator covers the contractor establishing and maintaining a register of patients with coronary heart disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM235
This indicator covers the contractor establishing and maintaining a register of all cancer patients excluding non-melanotic skin cancers. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM234
Diabetes: blood pressure (without moderate or severe frailty) (IND249)
This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233
our guideline on RArheumatoid arthritis and guideline on SpAspondyloarthritis . To ensure an accurate and timely diagnosis,...
Using NICE guidance in social work: examples for principal social workers
A range of fictional scenarios which show how NICE's guidelines and quality standards could be used by principal social workers.
up for me and a toilet seat. I felt much safer. Later in the day a really nice carer with a big smile on his face came in and said he...
How voluntary and community sector (VCS) organisations can help us develop guidance
Support for organisations who contribute to developing our guidance
Tailored content for our communities: Medicines and prescribing, general practice, social care, the public, library and knowledge services and local government.